iShares Nasdaq BioTech ETF

IBB-Q

NASDAQ:IBB

120.03
1.17 (0.98%)

Analysis and Opinions about IBB-Q

Signal
Opinion
Expert
PAST TOP PICK
PAST TOP PICK
October 18, 2019
(A Top Pick May 06/19, Down 6%) What did not happen this year was there was not the usual seasonal uptick in June. A long term hold. He thinks biotech is the next wave that drives markets for the next generation. Everyone should own biotech in their portfolio.
(A Top Pick May 06/19, Down 6%) What did not happen this year was there was not the usual seasonal uptick in June. A long term hold. He thinks biotech is the next wave that drives markets for the next generation. Everyone should own biotech in their portfolio.
Hap (Robert) Sneddon FCSI
Chief Portfolio Manager & Founder, Castlemoore Inc.
Price
$102.270
Owned
Yes
PAST TOP PICK
PAST TOP PICK
August 29, 2019
(A Top Pick Jun 20/19, Down 5%) A pick from his aggressive growth strategy, so you get more volatility. Sees support. If there's a 10% bump, then he'll sell.
(A Top Pick Jun 20/19, Down 5%) A pick from his aggressive growth strategy, so you get more volatility. Sees support. If there's a 10% bump, then he'll sell.
Keith Richards
Portfolio Manager, ValueTrend Wealth Management
Price
$103.620
Owned
Yes
TOP PICK
TOP PICK
June 20, 2019
Not for everybody. This is for the more aggressive mandates. The expense ratio is 47 basis points. This is for rapid trading. He thinks it will get to the $115 target.
Not for everybody. This is for the more aggressive mandates. The expense ratio is 47 basis points. This is for rapid trading. He thinks it will get to the $115 target.
Keith Richards
Portfolio Manager, ValueTrend Wealth Management
Price
$108.620
Owned
Yes
TOP PICK
TOP PICK
June 7, 2019
Healthcare is a great secular play, though a political hot potato in the US. Now is a good seasonal play for biotech stocks, but you must hold this long term.
Healthcare is a great secular play, though a political hot potato in the US. Now is a good seasonal play for biotech stocks, but you must hold this long term.
Hap (Robert) Sneddon FCSI
Chief Portfolio Manager & Founder, Castlemoore Inc.
Price
$103.830
Owned
Yes
TOP PICK
TOP PICK
May 6, 2019
It's entering seasonal strength, based on nice moves in the past two years. Biotech has been a hot potato in American politics, but is on the leading edge that will change society. These stocks are undervalued.
It's entering seasonal strength, based on nice moves in the past two years. Biotech has been a hot potato in American politics, but is on the leading edge that will change society. These stocks are undervalued.
Hap (Robert) Sneddon FCSI
Chief Portfolio Manager & Founder, Castlemoore Inc.
Price
$108.830
Owned
Yes
HOLD
HOLD
May 3, 2019
Diversity is key in the space. Has a lot of small caps, so will increase volatility. If you can buy a basket of large cap biotechs, that would be the way to go right now. In this space, buy the basket is the most prudent way to go. Individual names bring high risk.
Diversity is key in the space. Has a lot of small caps, so will increase volatility. If you can buy a basket of large cap biotechs, that would be the way to go right now. In this space, buy the basket is the most prudent way to go. Individual names bring high risk.
Paul MacDonald
Chief Investment Officer & Portfolio Manager, Harvest Portfolios Group
Price
$107.910
Owned
Unknown
TOP PICK
TOP PICK
April 18, 2019
He believes in U.S. biotech which is mostly this ETF (and 10% pharma, plus life sciences). Considering the backdrop of an aging population.
He believes in U.S. biotech which is mostly this ETF (and 10% pharma, plus life sciences). Considering the backdrop of an aging population.
David Cockfield
Managing Director, Northland Wealth Management
Price
$104.540
Owned
Yes
PAST TOP PICK
PAST TOP PICK
March 7, 2019
(A Top Pick Feb 02/18, Down 3%) Not a bad return given the markets we've had over the last year.
(A Top Pick Feb 02/18, Down 3%) Not a bad return given the markets we've had over the last year.
David Cockfield
Managing Director, Northland Wealth Management
Price
$109.140
Owned
Yes
PAST TOP PICK
PAST TOP PICK
October 15, 2018

(A Top Pick Nov. 17/17, Up 7%) There was a three for one stock split. This and healthcare are in a long term secular bull market. You have to live with the volatility and this is why he likes the ETF. He would hold it long term.

(A Top Pick Nov. 17/17, Up 7%) There was a three for one stock split. This and healthcare are in a long term secular bull market. You have to live with the volatility and this is why he likes the ETF. He would hold it long term.

Hap (Robert) Sneddon FCSI
Chief Portfolio Manager & Founder, Castlemoore Inc.
Price
$110.090
Owned
Yes
TOP PICK
TOP PICK
September 14, 2018

It's in a long-term bull market and has beaten the S&P. Resistence in the high $120's. Biotech is good because unlike regular pharma stocks, you don't have to be worry about generic drugs to compete with you. Buying the ETF lowers volatility than individual stocks.

It's in a long-term bull market and has beaten the S&P. Resistence in the high $120's. Biotech is good because unlike regular pharma stocks, you don't have to be worry about generic drugs to compete with you. Buying the ETF lowers volatility than individual stocks.

Hap (Robert) Sneddon FCSI
Chief Portfolio Manager & Founder, Castlemoore Inc.
Price
$117.770
Owned
Yes
PAST TOP PICK
PAST TOP PICK
August 13, 2018

(Past Top Pick on Sept 21, 2017, Up 6%) Has enjoyed a nice trend though it fell to $105 (in April) which is a test level. It's volatile, but every portfolio must hold biotech, which is what this ETF carries.

(Past Top Pick on Sept 21, 2017, Up 6%) Has enjoyed a nice trend though it fell to $105 (in April) which is a test level. It's volatile, but every portfolio must hold biotech, which is what this ETF carries.

Hap (Robert) Sneddon FCSI
Chief Portfolio Manager & Founder, Castlemoore Inc.
Price
$116.560
Owned
Yes
PAST TOP PICK
PAST TOP PICK
June 15, 2018

(A Top Pick September 21 / 2017, Up 1%) Still likes. Could have sold it earlier for a nice gain, but deep story on long-term basis, pricing issues that the industry’s going to have to deal with. If we can get above $120 with some volume, going to be really good. Great time to get into biotechs seasonally right now. Good place to be throughout the summer, but also on long-term basis. Still buying at these prices.

(A Top Pick September 21 / 2017, Up 1%) Still likes. Could have sold it earlier for a nice gain, but deep story on long-term basis, pricing issues that the industry’s going to have to deal with. If we can get above $120 with some volume, going to be really good. Great time to get into biotechs seasonally right now. Good place to be throughout the summer, but also on long-term basis. Still buying at these prices.

Hap (Robert) Sneddon FCSI
Chief Portfolio Manager & Founder, Castlemoore Inc.
Price
$111.260
Owned
Yes
TOP PICK
TOP PICK
February 2, 2018

He believes in the biotech sector. It is a concept play considering aging population. ETF that allows you to participate in many companies that would require a lot of analysis.

He believes in the biotech sector. It is a concept play considering aging population. ETF that allows you to participate in many companies that would require a lot of analysis.

David Cockfield
Managing Director, Northland Wealth Management
Price
$112.140
Owned
Yes
COMMENT
COMMENT
January 19, 2018

A very, very large ETF. You can take a look at the different ones. There is a great website ETF.COM where you could look at this, and it will show you some of its competitors. He thinks this is a good sector to be in.

A very, very large ETF. You can take a look at the different ones. There is a great website ETF.COM where you could look at this, and it will show you some of its competitors. He thinks this is a good sector to be in.

John Hood
President & Portfolio Manager, J. C Hood Investment.
Price
$112.000
Owned
Unknown
COMMENT
COMMENT
December 7, 2017

Sold Amgen (AMGN-Q) and bought this. Good move? He likes biotechs, but you need to recognize that it is a higher beta space and will be more volatile than other areas or other industries. There are some names in this he likes, but there are a couple that are not doing so well. He would rather pick and choose individual names, but that is going to create more risk because you are going to concentrate on 1 or 2 names. With IBB you get a more diversified risk. Thinks the space is going to do fine.

Sold Amgen (AMGN-Q) and bought this. Good move? He likes biotechs, but you need to recognize that it is a higher beta space and will be more volatile than other areas or other industries. There are some names in this he likes, but there are a couple that are not doing so well. He would rather pick and choose individual names, but that is going to create more risk because you are going to concentrate on 1 or 2 names. With IBB you get a more diversified risk. Thinks the space is going to do fine.

Stan Wong
Director & Portfolio Manager, Private Wealth Management, ScotiaMcleod
Price
$104.050
Owned
Unknown
Showing 1 to 15 of 63 entries